4 completed, 2 terminated. 5 Phase 2, 1 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow Maraviroc 300 mg: new trials by email Literature Review of Maraviroc 300 mg trials Research Report on Maraviroc 300 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Maraviroc for Post-stroke Depression Maraviroc 300 mg - Post-stroke Depression | Phase 2 | Completed | Tel-Aviv Sourasky Medical Center | 10 | 2020-08-04 | 2023-07-06 |
| Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19). Maraviroc 300 mg, Standard care therapy - COVID-19 | Phase 2 | Terminated | Hospital Universitario Infanta Leonor | 60 | 2020-06-26 | 2022-03-11 |
| Maraviroc to Augment Rehabilitation Outcomes After Stroke Maraviroc 300 mg, Rehabilitation therapy, Placebo 300 mg - Stroke | Phase 2 / Phase 3 | Terminated | University of California, Los Angeles | 2 | 2019-08-01 | 2021-08-03 |
| Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients. Maraviroc 300 mg - HIV Infection With Other Conditions, Cardiovascular Risk Factor | Phase 4 | Completed | University Of Perugia | 22 | 2015-01-01 | 2018-01-23 |
| Phase II Maraviroc for GVHD Prevention Maraviroc 300 mg - Hematologic Malignancy | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 37 | 2013-02-01 | 2021-01-11 |
| Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation Maraviroc 150 MG, Maraviroc 300 mg, Maraviroc 300 mg Phase II - Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation | Phase 1 / Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 38 | 2009-06-01 | 2022-05-17 |
Atherosclerosis (1) · COVID-19 (1) · Graft vs Host Disease (1) · Hematologic Neoplasms (1) · Inflammation (1) · Respiratory Distress Syndrome (1) · Stroke (1)
Abramson Cancer Center at Penn Medicine (2) · Hospital Universitario Infanta Leonor (1) · Tel-Aviv Sourasky Medical Center (1) · University Of Perugia (1) · University of California, Los Angeles (1)
United States (2) · Israel (1) · Italy (1) · Spain (1)
David Porter, MD (2)